 This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mgm2 on days 1, 4, 8, and 11 to determine the MTD in combination with lenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle for patients with myelodysplastic syndrome. 